Biotech stocks decline 5%+ within 90 days of new FDA chief

Historical patterns show biotech stocks often decline following leadership changes at the FDA. A new chief would likely trigger a short-term sell-off in the sector amid regulatory uncertainty.

Implied probability (Yes)

70%